7460-82-4

Basic information

• Product Name: DIETHYLENE GLYCOL BIS(P-TOLUENESULFONATE)
• Synonyms: 2-[2-(p-tolylsulfonyloxy)ethoxy]ethyl 4-methylbenzenesulfonate;Diethylene glycol bis(p-toluenesulfonate)≥ 99%(HPLC);2,2'-OXYDIETHYL DITOSYLATE;BIS(2-TOSYLOXYETHYL) ETHER;BIS[2-(P-TOLUENESULFONYLOXY)ETHYL] ETHER;DI(ETHYLENE GLYCOL) DI-P-TOSYLATE;DIETHYLENE GLYCOL DITOSYLATE;DIETHYLENE GLYCOL BIS(P-TOLUENESULFONATE)
• CAS NO: 7460-82-4
• Molecular Formula: C₁₈H₂₂O₇S₂
• Molecular Weight: 414.49
• EINECS: 1312995-182-4
• Product Categories: CMLLYL
• Mol File: 7460-82-4.mol
• Article Data: 103

Chemical Properties

• Melting Point: 87-89 °C(lit.)
• Boiling Point: 581.2 °C at 760 mmHg
• Flash Point: 305.3 °C
• Appearance: colorless to white powder or crystals
• Density: 1.301 g/cm³
• Vapor Pressure: 6.78E-13mmHg at 25°C
• Refractive Index: 1.554
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: Chloroform (Slightly), Ethyl Acetate (Slightly)
• BRN: 583800
• CAS DataBase Reference: DIETHYLENE GLYCOL BIS(P-TOLUENESULFONATE)(CAS DataBase Reference)
• NIST Chemistry Reference: DIETHYLENE GLYCOL BIS(P-TOLUENESULFONATE)(7460-82-4)
• EPA Substance Registry System: DIETHYLENE GLYCOL BIS(P-TOLUENESULFONATE)(7460-82-4)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• Hazardous Substances Data: 7460-82-4(Hazardous Substances Data)

Usage

Uses

Used in Crown Ether Synthesis:
DIETHYLENE GLYCOL BIS(P-TOLUENESULFONATE) is used as a key intermediate in the synthesis of various crown ether macrocycles, such as bis(dibenzosulfoxo)-27,30,35,38-tetramethyl-24-crown-6, bis(dibenzosulfoxo)-21,24,29,32-tetramethyl-18-crown-4, dibenzosulfoxo-15,18-dimethyl-12-crown-3, and dibenzosulfoxo-12,15-dimethyl-9-crown-2. These macrocycles are synthesized for their potential applications in ion recognition, catalysis, and molecular assembly.

Purification Methods

Purify the ester by recrystallisation from Me2CO and dry it in a vacuum. [Beilstein 11 III 225.]

InChI:InChI=1/C18H22O7S2/c1-15-3-7-17(8-4-15)26(19,20)24-13-11-23-12-14-25-27(21,22)18-9-5-16(2)6-10-18/h3-10H,11-14H2,1-2H3

Upstream product

• 103057-51-8 hypochlorous acid 4-methylbenzene sulfonic anhydride 
• 111-46-6 diethylene glycol 
• 98-59-9 p-toluenesulfonyl chloride 

Downstream Products

• 82645-24-7 1,5-bis(benzaldehydeoxy)-3-oxopentane 
• 4394-85-8 4-morpholinecarboxaldehyde 
• 23116-94-1 bis(2-hydroxyphenoxyethyl)ether 
• 143994-73-4 2-Benzylsulfanylmethyl-1,4,7,10-tetraoxa-cyclododecane 
• 60147-25-3 4-oxa-1,7-bis(p-toluenesulphonyl)-1,7-diazacyclodecane 
• 111660-66-3 (2R)-(1'S,2'R,4'S,6'S,9'R)-2'-(4',9'-diphenyl-3',5',8',10'-tetraoxabicyclo<4.4.0>decyl)-1,4,7-trioxacyclononane 
• 111660-64-1 (2R,12R)-di((1'S,2'R,4'S,6'S,9'R)-2'-(4',9'-diphenyl-3',5',8',10'-tetraoxabicyclo<4.4.0>decyl))-1,4,7,10,13,16-hexaoxacyclooctadecane 
• 69649-51-0 (2R,4aR,6S,7R,8R,8aR)-6-Methoxy-8-(2-{2-[(2R,4aR,6S,7R,8S,8aR)-6-methoxy-2-phenyl-7-(2-vinyloxy-ethoxy)-hexahydro-pyrano[3,2-d][1,3]dioxin-8-yloxy]-ethoxy}-ethoxy)-2-phenyl-hexahydro-pyrano[3,2-d][1,3]dioxin-7-ol 
• 67077-32-1 Bis(methyl-4,6-O-benzyliden-2,3-dideoxy-α-D-glucopyranosido<2,3-b><2',3'-k>)-1,4,7,10,13,16-hexaoxacyclooctadecan 

Relevant articles and documents

Isatin–Coumarin Hybrids Tethered via Diethylene Glycol: Design, Synthesis, and Their In Vitro Antitumor Activities

A series of novel isatin–coumarin hybrids was designed, synthesized, and assessed for their in vitro antitumor activities against drug-sensitive HepG2, Hela, A549, DU145 (prostatic cancer), SKOV3, and MCF-7 as well as drug-resistant MCF-7/DOX (doxorubicin

Design, Synthesis, and Antimycobacterial Activities of Diethylene Glycol Tethered Moxifloxacin–Isatin Hybrids

A new class of diethylene glycol tethered moxifloxacin–isatin hybrids 5a–l was designed, synthesized, and evaluated for their in vitro antimycobacterial activity against Mycobacterium tuberculosis (MTB) H37Rv and multidrug-resistant tuberculosis (MDR-TB)

Gatifloxacin–Isatin Hybrids and Their Antimycobacterial Activities

We report herein the design, synthesis, and antimycobacterial activity of a series of diethylene glycol tethered gatifloxacin–isatin hybrids 5a–o in this paper. Results revealed that all hybrids showed promising activity against both drug-sensitive and mu

Ciprofloxacin–Isatin Hybrids and Their Antimycobacterial Activities

A series of diethylene glycol tethered ciprofloxacin–isatin hybrids 5a–j were designed, synthesized, and evaluated for their in vitro antimycobacterial activity against both drug-sensitive and multidrug-resistant (MDR) Mycobacterium tuberculosis strains i

Visible light-activatable cyclodextrin-conjugates for the efficient delivery of nitric oxide with fluorescent reporter and their inclusion complexes with betaxolol

This contribution reports the design, synthesis, photochemical properties and drug inclusion capability of two novel β-cyclodextrin (βCD) conjugates, βCD-NBFNO1 and βCD-NBFNO2, covalently integrating an N-nitroso amino-nitro-benzofurazan in the primary and secondary hydroxyl rims of the βCD scaffold, respectively through flexible spacers of different length. Both βCD conjugates are water-soluble and release nitric oxide (NO) under the input of either blue or green light, with quantum yields ΦNO (blue) = 0.13, 0.31 and ΦNO (green) = 0.007, 0.013 respectively, the former representing the largest values ever reported for nonmetal-containing NO donors activatable by visible light. The good contrast between the fluorescence green emission of the chromogenic moiety after and before the NO release permits the easy and in real-time quantification of the amount of NO generated, without the addition of external fluorescent agents. Despite the presence of the appendages, these βCD derivatives are also able to complex betaxolol, a β-blocker drug widely used for the reduction of the intraocular pressure, with binding constants Kb = 500 ± 50 and 1100 ± 100 M-1, respectively, without affecting the photochemical performances. In view of the well-known vasodilator properties of NO, the present βCD derivatives represent intriguing candidates for biopharmaceutical research studies addressed to combined therapeutic ocular applications.

Catalytic Synthesis of PEGylated EGCG Conjugates that Disaggregate Alzheimer's Tau

The naturally occurring flavonoid ( )-epigallocatechin gallate (EGCG) is a potent disaggregant of tau fibrils. Guided by the recent cryo-electron microscopy (cryoEM) structure of EGCG bound to fibrils of tau derived from an Alzheimer s brain donor, methods to site-specifically modify the EGCG D-ring with aminoPEGylated linkers are reported. The resultant molecules inhibit tau fibril seeding by Alzheimer s brain extracts. Formulations of aminoPEGylated EGCG conjugated to the (quasi)-brain-penetrant nanoparticle Ferumoxytol inhibit seeding by AD-tau with linker length affecting activity. The protecting groupfree catalytic cycloaddition of amino azides to mono-propargylated EGCG described here provides a blueprint for access to stable nanoparticulate forms of EGCG potentially useful as therapeutics to eliminate Alzheimer s-related tau tangles.

AGENTS AND METHODS FOR TREATING TAUOPATHIES

Disclosed are agents that include a flavanol (e.g., epigallocatechm-3-gailate) or a flavanol analog, a linker coupled to the flavanol or the flavanol analog, and a earner (e.g., iron oxide nanoparticle) coupled to the linker. The disclosed agents can be u

Design and Synthesis of Oleanolic Acid Trimers to Enhance Inhibition of Influenza Virus Entry

Influenza is a major threat to millions of people worldwide. Entry inhibitors are of particular interest for the development of novel therapeutic strategies for influenza. We have previously discovered oleanolic acid (OA) to be a mild influenza hemagglutinin (HA) inhibitor. In this work, inspired by the 3D structure of HA as a homotrimeric receptor, we designed and synthesized 15 OA trimers with different linkers and central region via the copper-catalyzed azide-alkyne cycloaddition reaction. All of the OA trimers were evaluated for their antiviral activities in vitro, and 12c, 12e, 13c, and 13d were observed to exhibit robust potency (IC50 in the submicromolar range) against influenza A/WSN/33 (H1N1) virus that was stronger than that observed with oseltamivir. In addition, these compounds also displayed strong biological activity against A/Hong Kong/4801/2014 and B/Sichuan/531/2018 (BV). The results of hemagglutination inhibition assays and surface plasmon resonance binding assays suggest that these OA trimers may interrupt the interaction between the HA protein of influenza virus and the host cell sialic acid receptor, thus blocking viral entry. These findings highlight the utility of multivalent OA conjugates to enhance the ligand-target interactions in anti-influenza virus drug design and are also helpful for studying antiviral drugs derived from natural products.

QUINAZOLINES COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF

The present invention discloses a compound of anilino polyethylene glycol ether cycloquinazoline substituted with a substituted arylmethyl heteroatomic group having the structure of formula (I) below, or a pharmaceutically acceptable salt, ester or solvate thereof, and a pharmaceutical composition comprising the same. The compound and pharmaceutical composition disclosed herein can be used in tumor targeted therapy and in the regulation of tumors and related diseases.

COMPOUNDS USEFUL IN HIV THERAPY

The invention relates to compounds of Formula (I), (Ia), (Ib), (II) or (III), salts thereof, pharmaceutical compositions thereof, as well as therapeutic methods of treatment and prevention.